DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor

Abstract

Signaling downstream of the receptor of parathyroid hormone (PTH1R) exerts two major skeletal effects: increases bone remodeling and, when stimulated intermittently, induces bone anabolism. Osteocytes express the PTH1R and are critical for the action of teriparatide/parathyroid hormone 1–34 (PTH). However, it is unknown whether they also mediate the effects of abaloparatide (a 34 amino acid synthetic analog of human parathyroid hormone-related protein, ABL), and whether actions on osteocytes are required for the increase in remodeling and/or the bone gain induced by PTH/ABL in diabetes. We addressed these questions by treating with PTH or ABL control or diabetic (DM) mice lacking the PTH1R in DMP1-Cre expressing cells that targets all osteocytes (cKO). Both PTH and ABL increased bone mass and improved or corrected cortical and trabecular bone microarchitecture only in fl/fl littermates but not in cKO, control or DM mice. Further, PTH/ABL increased bone strength and microindentation resistance only in control or DM fl/fl mice. In contrast, PTH/ABL increased serum P1NP and bone formation on cancellous, periosteal and endocortical surfaces, in control or DM mice of both genotypes. Moreover, serum CTX and osteoclast surface were increased by PTH/ABL in fl/fl and cKO, control or DM mice. Thus, actions on DMP1-Cre expressing cells are required for bone gain, microarchitecture restoration, strength and resistance to fracture, exerted by PTH and ABL under physiological and DM conditions, but not for the increase in bone remodeling. These findings demonstrate the dissociation of bone gain from bone remodeling and reveal that actions on DMP1-Cre expressing cells drive the gain in bone mass and strength induced by PTH and ABL.

References

[1] Sun H, et al.. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diab. Res. Clin. Pract., 2022, 183: 109119

[2] Hofbauer LC, et al.. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diab. Endocrinol., 2022, 10: 207-220

[3] Shen Q, Ma Y. Impact of diabetes mellitus on risk of major complications after hip fracture: a systematic review and meta-analysis. Diabetol. Metab. Syndr., 2022, 14: 51

[4] Marino S, Bellido T. PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus. Nat. Rev. Endocrinol., 2024, 20: 661-672

[5] Dhaliwal R, et al.. Abaloparatide in postmenopausal women with osteoporosis and type 2 diabetes: a post hoc analysis of the ACTIVE study. JBMR, 2020, 4: e10346

[6] Schwartz AV, et al.. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone, 2016, 91: 152-158

[7] Munekawa, C. et al. Effect of teriparatide on bone mineral density and trabecular bone score in type 2 diabetic patients with osteoporosis: a retrospective cohort study. Medicina (Kaunas)58, 481 (2022).

[8] Sølling ASK, Harsløf T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Therapeutic Adv. Musculoskelet. Dis., 2018, 10: 105-115

[9] Marino S, et al.. Reversal of the diabetic bone signature with anabolic therapies in mice. Bone Res, 2023, 11: 19

[10] O’Brien CA, et al.. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One, 2008, 3: e2942

[11] Delgado-Calle J, et al.. Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor. J. Bone Miner. Res., 2017, 32: 522-535

[12] Marino, S. et al. Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice. Bone, 181, 117042 (2024).

[13] Samuel J, Sinha D, Zhao JC, Wang X. Water residing in small ultrastructural spaces plays a critical role in the mechanical behavior of bone. Bone, 2014, 59: 199-206

[14] Nyman JS, et al.. Partial removal of pore and loosely bound water by low-energy drying decreases cortical bone toughness in young and old donors. J. Mech. Behav. Biomed. Mater., 2013, 22: 136-145

[15] Nyman JS, et al.. Toward the use of MRI measurements of bound and pore water in fracture risk assessment. Bone, 2023, 176: 116863

[16] Kalajzic I, et al.. In vitro and in vivo approaches to study osteocyte biology. Bone, 2013, 54: 296-306

[17] Fu, Q. et al. Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight8, e167790 (2023).

[18] Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone, 2013, 54: 250-257

[19] Powell WF, et al.. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J. Endocrinol., 2011, 209: 21-32

[20] Parfitt, A. M. in Osteoporosis 315–329 (Academic Press, 1996).

[21] Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J. Bone Miner. Res, 2002, 17: 1558-1559

[22] Tu X, et al.. Osteocytes mediate the anabolic actions of canonical Wnt/b-catenin signaling in bone. Proc. Natl. Acad. Sci. USA, 2015, 112: E478-E486

[23] Lekkala S, Taylor EA, Hunt HB, Donnelly E. Effects of diabetes on bone material properties. Curr. Osteoporos. Rep., 2019, 17: 455-464

[24] Qian W, et al.. Bone intrinsic material and compositional properties in postmenopausal women diagnosed with long-term Type-1 diabetes. Bone, 2023, 174: 116832

[25] Eckhardt, B. A. et al. Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. JCI Insight5, e135236 (2020).

[26] Wang X, Xu H, Huang Y, Gu S, Jiang JX. Coupling effect of water and proteoglycans on the in situ toughness of bone. J. Bone Miner. Res., 2016, 31: 1026-1029

[27] Rao G, et al.. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia, 2011, 54: 1527-1538

[28] Piccoli A, et al.. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J. Bone Miner. Res., 2020, 35: 2415-2422

[29] Kobayashi T, et al.. PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development, 2002, 129: 2977-2986

[30] Bivi N, et al.. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J. Bone Miner. Res., 2012, 27: 374-389

[31] Creecy A, et al.. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age. Bone, 2018, 110: 204-214

[32] Sato AY, et al.. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin. J. Bone Miner. Res., 2016, 31: 1791-1802

[33] Bouxsein ML, et al.. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res., 2010, 25: 1468-1486

[34] Creecy A, et al.. The age-related decrease in material properties of BALB/c mouse long bones involves alterations to the extracellular matrix. Bone, 2020, 130: 115126

[35] Ahmed R, et al.. Identifying bone matrix impairments in a mouse model of neurofibromatosis type 1 (NF1) by clinically translatable techniques. J. Bone Miner. Res., 2022, 37: 1603-1621

[36] Horch RA, Nyman JS, Gochberg DF, Dortch RD, Does MD. Characterization of 1H NMR signal in human cortical bone for magnetic resonance imaging. Magn. Reson Med, 2010, 64: 680-687

[37] Lane NE, et al.. Inhibition of vascular endothelial growth factor in young adult mice causes low bone blood flow and bone strength with no effect on bone mass in trabecular regions. Bone Rep., 2019, 10: 100210

[38] Dempster DW, et al.. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res, 2013, 28: 2-17

Funding

U.S. Department of Veterans Affairs (Department of Veterans Affairs)(I01 BX002104)

RIGHTS & PERMISSIONS

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply